These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2720134)

  • 1. Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets.
    Moreland TA; McMurdo ME; McEwen J
    Biopharm Drug Dispos; 1989; 10(3):311-9. PubMed ID: 2720134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet.
    McEwen J; Durnin C; McMurdo ME; Moreland TA
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S57-9. PubMed ID: 2475689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation.
    Sawicki W; Janicki S
    Int J Pharm; 2002 May; 238(1-2):181-9. PubMed ID: 11996822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of food on the bioavailability of a sustained-release verapamil preparation.
    Conway EL; Phillips PA; Drummer OH; Louis WJ
    J Pharm Sci; 1990 Mar; 79(3):228-31. PubMed ID: 2338632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.
    Mattila J; Mäntylä R; Taskinen J; Männistö P
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):133-8. PubMed ID: 3840089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
    Jørgensen NP; Walstad RA
    Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans.
    Sawicki W
    Eur J Pharm Biopharm; 2002 Jan; 53(1):29-35. PubMed ID: 11777750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity.
    Bhatti MM; Lewanczuk RZ; Pasutto FM; Foster RT
    J Clin Pharmacol; 1995 Nov; 35(11):1076-82. PubMed ID: 8626881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of oral sustained-release and regular-release oxprenolol tablets at steady-state.
    Gupta PK; Lim JK; Zoest AR; Lam FC; Hung CT
    Biopharm Drug Dispos; 1991 Oct; 12(7):493-503. PubMed ID: 1932612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation.
    Harder S; Thürmann P; Siewert M; Blume H; Huber T; Rietbrock N
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):207-12. PubMed ID: 1709224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of verapamil in patients with hypertension.
    Anderson P; Bondesson U; de Faire U
    Eur J Clin Pharmacol; 1986; 31(2):155-63. PubMed ID: 3803414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel chewable sustained-release tablet containing verapamil hydrochloride.
    El-Gazayerly ON; Rakkanka V; Ayres JW
    Pharm Dev Technol; 2004; 9(2):181-8. PubMed ID: 15202577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
    Gupta SK; Atkinson L; Tu T; Longstreth JA
    Br J Clin Pharmacol; 1995 Oct; 40(4):325-31. PubMed ID: 8554934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    Drugs; 1992; 44 Suppl 1():1-11. PubMed ID: 1283570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
    Gupta SK; Yih BM; Atkinson L; Longstreth J
    J Clin Pharmacol; 1995 Nov; 35(11):1083-93. PubMed ID: 8626882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of two formulations of verapamil.
    Hla KK; Henry JA; Latham AN
    Br J Clin Pharmacol; 1987 Nov; 24(5):661-4. PubMed ID: 3435694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.
    Popović J; Mitić R; Sabo A; Mikov M; Jakovljević V; Daković-Svajcer K
    Eur J Drug Metab Pharmacokinet; 2006; 31(2):87-96. PubMed ID: 16898076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs.
    Yassin AE; Alkhaled F; al-Suwayeh S; Elkheshen S
    Boll Chim Farm; 2003 Sep; 142(7):285-9. PubMed ID: 14677272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both.
    Karim A; Piergies A
    Clin Pharmacol Ther; 1995 Aug; 58(2):174-84. PubMed ID: 7648767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.